FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201822124> ?p ?o ?g. }

• W3201822124 endingPage "S950" @default.
• W3201822124 startingPage "S950" @default.
• W3201822124 abstract "Adding bevacizumab to erlotinib prolonged PFS in NEJ026 and CTONG 1509 trials, but limited data are available in non-Asian patients (pts). BEVERLY is an Italian no-profit, randomized, open-label, multicenter phase III trial of bevacizumab (BEV) plus erlotinib (E) vs E alone as first-line treatment for EGFR-mutated advanced NSCLC. Eligible pts were randomized 1:1 to E (150mg daily) alone or combined with BEV (15mg/kg iv q3w) until disease progression or unacceptable toxicity. Center, ECOG PS and type of mutation (ex19 deletion vs ex21 L858R vs others) were stratification variables. Co-primary endpoints were investigator-assessed PFS (IA-PFS) and blinded-independent centrally-reviewed PFS (BICR-PFS). Secondary endpoints were OS, QoL, IA- and BICR- objective response rate (ORR) and safety; biomarker analyses are also planned. 126 events out of 160 randomized pts were required to detect a PFS prolongation with BEV from 10 to 16.7 mos (HR 0.60), with 2-sided α=0.05, 80% power. From Apr 11, 2016 to Feb 27, 2019, 160 pts were randomized to BEV+E (80) or E alone (80). Pts were mainly female (63.8%), never smokers (51.9%), ECOG PS 0-1 (98.1%), median age 66 (IQR 59-73); 55% of pts had ex19Del and 41% L858R mutation. At a median follow-up of 31 mos, 130/160 (81.3%) pts had a PFS event (progression or death) and 84/160 (52.5%) died. BEV+E significantly prolonged IA-PFS over E alone with a median of 15.4 vs 9.7 mos (HR 0.60; 95%CI 0.42-0.85, log-rank P=0.0039). Median OS was 28.4 vs 23.0 mos in BEV+E and E arms, respectively (HR 0.70; 95%CI 0.46-1.10, log-rank P=0.12). One toxic death was reported, due to intracranial hemorrhage with BEV+E. Hypertension (any grade: 49% vs 18%; grade≥3: 24% vs 5%), skin rash (grade≥3: 31% vs 14%), thromboembolic events (any grade: 11% vs 4%), and proteinuria (any grade: 23% vs 6%) were more frequent with the experimental combination treatment. The addition of BEV to E significantly prolonged IA-PFS compared with E alone as first-line treatment in Italian EGFR-mutated NSCLC patients, with no unexpected safety issues. Blinded radiologic revision of PFS and ORR is ongoing and will be presented at the meeting." @default.
• W3201822124 created "2021-10-11" @default.
• W3201822124 creator A5001464256 @default.
• W3201822124 creator A5003014678 @default.
• W3201822124 creator A5003664573 @default.
• W3201822124 creator A5005069846 @default.
• W3201822124 creator A5008403882 @default.
• W3201822124 creator A5012201620 @default.
• W3201822124 creator A5016655393 @default.
• W3201822124 creator A5023024840 @default.
• W3201822124 creator A5025474253 @default.
• W3201822124 creator A5044096432 @default.
• W3201822124 creator A5045384053 @default.
• W3201822124 creator A5051933262 @default.
• W3201822124 creator A5056026886 @default.
• W3201822124 creator A5056034569 @default.
• W3201822124 creator A5059597630 @default.
• W3201822124 creator A5064162399 @default.
• W3201822124 creator A5074749942 @default.
• W3201822124 creator A5085083712 @default.
• W3201822124 creator A5085427107 @default.
• W3201822124 creator A5091509029 @default.
• W3201822124 date "2021-09-01" @default.
• W3201822124 modified "2023-10-16" @default.
• W3201822124 title "1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial" @default.
• W3201822124 doi "https://doi.org/10.1016/j.annonc.2021.08.1812" @default.
• W3201822124 hasPublicationYear "2021" @default.
• W3201822124 type Work @default.
• W3201822124 sameAs 3201822124 @default.
• W3201822124 citedByCount "10" @default.
• W3201822124 countsByYear W32018221242021 @default.
• W3201822124 countsByYear W32018221242022 @default.
• W3201822124 countsByYear W32018221242023 @default.
• W3201822124 crossrefType "journal-article" @default.
• W3201822124 hasAuthorship W3201822124A5001464256 @default.
• W3201822124 hasAuthorship W3201822124A5003014678 @default.
• W3201822124 hasAuthorship W3201822124A5003664573 @default.
• W3201822124 hasAuthorship W3201822124A5005069846 @default.
• W3201822124 hasAuthorship W3201822124A5008403882 @default.
• W3201822124 hasAuthorship W3201822124A5012201620 @default.
• W3201822124 hasAuthorship W3201822124A5016655393 @default.
• W3201822124 hasAuthorship W3201822124A5023024840 @default.
• W3201822124 hasAuthorship W3201822124A5025474253 @default.
• W3201822124 hasAuthorship W3201822124A5044096432 @default.
• W3201822124 hasAuthorship W3201822124A5045384053 @default.
• W3201822124 hasAuthorship W3201822124A5051933262 @default.
• W3201822124 hasAuthorship W3201822124A5056026886 @default.
• W3201822124 hasAuthorship W3201822124A5056034569 @default.
• W3201822124 hasAuthorship W3201822124A5059597630 @default.
• W3201822124 hasAuthorship W3201822124A5064162399 @default.
• W3201822124 hasAuthorship W3201822124A5074749942 @default.
• W3201822124 hasAuthorship W3201822124A5085083712 @default.
• W3201822124 hasAuthorship W3201822124A5085427107 @default.
• W3201822124 hasAuthorship W3201822124A5091509029 @default.
• W3201822124 hasBestOaLocation W32018221241 @default.
• W3201822124 hasConcept C121608353 @default.
• W3201822124 hasConcept C126322002 @default.
• W3201822124 hasConcept C143998085 @default.
• W3201822124 hasConcept C168563851 @default.
• W3201822124 hasConcept C2776694085 @default.
• W3201822124 hasConcept C2777506169 @default.
• W3201822124 hasConcept C2777802072 @default.
• W3201822124 hasConcept C2778087573 @default.
• W3201822124 hasConcept C2779438470 @default.
• W3201822124 hasConcept C2909325608 @default.
• W3201822124 hasConcept C71924100 @default.
• W3201822124 hasConceptScore W3201822124C121608353 @default.
• W3201822124 hasConceptScore W3201822124C126322002 @default.
• W3201822124 hasConceptScore W3201822124C143998085 @default.
• W3201822124 hasConceptScore W3201822124C168563851 @default.
• W3201822124 hasConceptScore W3201822124C2776694085 @default.
• W3201822124 hasConceptScore W3201822124C2777506169 @default.
• W3201822124 hasConceptScore W3201822124C2777802072 @default.
• W3201822124 hasConceptScore W3201822124C2778087573 @default.
• W3201822124 hasConceptScore W3201822124C2779438470 @default.
• W3201822124 hasConceptScore W3201822124C2909325608 @default.
• W3201822124 hasConceptScore W3201822124C71924100 @default.
• W3201822124 hasFunder F4320307105 @default.
• W3201822124 hasFunder F4320307779 @default.
• W3201822124 hasLocation W32018221241 @default.
• W3201822124 hasOpenAccess W3201822124 @default.
• W3201822124 hasPrimaryLocation W32018221241 @default.
• W3201822124 hasRelatedWork W121706947 @default.
• W3201822124 hasRelatedWork W1667731616 @default.
• W3201822124 hasRelatedWork W2045061462 @default.
• W3201822124 hasRelatedWork W2340863814 @default.
• W3201822124 hasRelatedWork W2591243544 @default.
• W3201822124 hasRelatedWork W2804337541 @default.
• W3201822124 hasRelatedWork W2906578683 @default.
• W3201822124 hasRelatedWork W2943986043 @default.
• W3201822124 hasRelatedWork W2999270520 @default.
• W3201822124 hasRelatedWork W3181378320 @default.
• W3201822124 hasVolume "32" @default.
• W3201822124 isParatext "false" @default.
• W3201822124 isRetracted "false" @default.
• W3201822124 magId "3201822124" @default.
• W3201822124 workType "article" @default.